Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab and Dinutuximab in Relapsed/Refractory Neuroblastoma or Relapsed Osteosarcoma
NCT04751383Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2021
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of magrolimab in neuroblastoma and osteosarcoma (OS) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Percent of Participants With Grade 3 or Higher Adverse Events at 30 days and Cycle 1 Dose Limiting Toxicities of Magrolimab at 21 days. Started Aug 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
neuroblastomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT04751383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751383.